CERVOMED INC (CRVO)
(Delayed Data from NSDQ)
$16.98 USD
+1.27 (8.08%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $16.89 -0.09 (-0.53%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Income Statements
Fiscal Year end for CervoMed Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 7 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 15 | 16 | 25 | 16 | 12 |
Income After Depreciation & Amortization | -8 | -16 | -25 | -16 | -12 |
Non-Operating Income | 6 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -2 | -16 | -25 | -16 | -11 |
Income Taxes | 0 | 0 | 0 | -2 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -2 | -16 | -24 | -14 | -12 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -2 | -16 | -24 | -14 | -12 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -8 | -16 | -25 | -16 | -11 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -8 | -16 | -25 | -16 | -12 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.66 | NA | 1.30 | 0.72 | 0.09 |
Diluted EPS Before Non-Recurring Items | -0.82 | NA | -18.75 | -22.50 | -131.99 |
Diluted Net EPS (GAAP) | -0.82 | -11.47 | -18.75 | -22.50 | -131.99 |
Fiscal Year end for CervoMed Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 3.29 | 2.35 | 5.62 | 1.53 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 3.29 | 2.35 | 5.62 | 1.53 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 6.28 | 4.94 | 4.20 | 4.20 | 2.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.99 | -2.59 | 1.42 | -2.67 | -2.29 |
Non-Operating Income | 0.68 | 0.08 | 0.46 | 4.83 | 0.18 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -2.32 | -2.51 | 1.88 | 2.15 | -2.11 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.32 | -2.51 | 1.88 | 2.15 | -2.11 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.32 | -2.51 | 1.88 | 2.15 | -2.11 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 8.70 | 6.17 | NA | 3.77 | 1.36 |
Diluted EPS Before Non-Recurring Items | -0.27 | -0.41 | NA | -0.70 | -1.56 |
Diluted Net EPS (GAAP) | -0.27 | -0.41 | 4.36 | -0.70 | -1.56 |